Abstract:Fibrosis, the excessive accumulation of extracellular matrix and mesenchymal cells, is a common major pathway to organ injury and failure.1 Fibrosis can affect virtually any organ of the body ultimately leading to organ failure, which accounts for at least one-third of deaths worldwide.2 Intestinal fibrosis and associated complications such as intestinal strictures are common in patients with Crohn's disease (CD) and ulcerative colitis.3 Despite progress in anti-inflammation therapy such as biological therapies, the percentage of patients undergoing surgery has remained largely unchanged over time.4 Endoscopic intervention or surgery may provide intermittent relief of symptoms to patients with CD-associated intestinal strictures. However, more than two-thirds of patients experience endoscopic recurrence at one year, while close to half of CD patients need a further intervention at 4 years.5 The mechanisms of intestinal fibrosis in inflammatory bowel disease (IBD) remain largely unclear, which hinders the development of specific anti-fibrotic drugs. Both inflammation-dependent and inflammation-independent mechanisms contribute to intestinal fibrosis.4 Immune components, including cytokine networks, host–microbiome interactions, and immune cell trafficking, play an important role in the pathogenesis of IBD and intestinal fibrosis.4 As a major cell type involved in fibrogenesis, myofibroblasts have been found to have a plastic and heterogeneous function in the process of producing abundant extracellular matrix. Recent immunological research suggests that numerous cytokines and chemokines from macrophages, T cells and other myeloid cell types are important drivers of myofibroblast activation and differentiation, with transforming growth factor (TGF)-β providing a critical link.6 It has been well established that there are metabolic changes of glycolysis, fatty acid oxidation, and glutamine metabolism during fibrosis in multiple organs such as lungs and kidneys;7 however, data from the intestine are limited. There are many clinical trials of potential drugs targeting enzymes involved in glycolysis and peroxisome proliferators-activated receptor (PPAR) signaling at present exploring their efficacy against fibrosis.8 Metabolic reprogramming may be a potential therapeutic strategy for intestinal fibrosis. The mesentery is increasingly recognized as playing a role in intestinal inflammation, and the inclusion of the mesentery in ileocolic resection for CD is associated with reduced frequency of resection after an initial resection.9 Emerging data indicate that there is a mechanistic interaction between creeping fat, muscularis propria hyperplasia, and stricturing disease. Investigating the interface between mesenteric fat and intestinal muscle may provide novel clues to fill the fundamental gap on our knowledge of the role of the unique components of creeping fat in intestinal strictures.10 A major unmet need in clinical practice is the early detection of fibrosis in IBD, which is of paramount importance in enabling early clinical interventions aimed at preventing the narrowing of the intestinal lumen. To this end, cross-sectional imaging modalities such as magnetic resonance enterography and bowel ultrasound have been investigated to distinguish inflammation from fibrosis and grade their severity.11 Other than basic descriptive information such as pre-stenotic dilation and luminal narrowing, high-dimensional data may be extracted from cross-sectional images, which has led to the use of the term “radiomics.” As an emerging translational field, radiomics abstracts data from standard-of-care medical images and aims to facilitate clinical decision-making with improved diagnostic, prognostic, and predictive accuracy. Radiomics has great potential as an application in all diseases, including IBD intestinal fibrosis.12 The endoscopic dilatation of strictures is suitable for short-segment isolated small bowel strictures. In selected cases, endoscopic treatment such as dilation provides a bridging therapy in the medical and surgical management of complications associated with IBD, including intestinal strictures.13 Other options are to divide the stricture surgically but preserve length (strictureplasty) or resect the strictured segment. Novel surgical techniques and approaches to intervene endoscopically on strictures are on the horizon. With the rapid research progress in this field, the hope of developing a specific anti-fibrotic therapy for IBD and reversing fibrotic strictures is becoming increasingly feasible. The Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium was established to build standardized clinical trial end-points for fibrostenosing CD.14 The development of clinical trial end-points, including a patient-reported outcome tool, cross-sectional imaging indices, and a histopathology index are now in process.15 In this series of review articles for this special issue, the latest mechanisms and clinical management tools for intestinal fibrosis in IBD are summarized, giving the reader a comprehensive overview of the mechanisms, diagnosis and potential treatment for fibrostenotic IBD. The chapters of reviews were carefully selected and are both timely and relevant. The authors should be congratulated and applauded for bringing the readers’ attention to this important topic.

Development of Antifibrotic Therapy for Stricturing Crohn’s Disease: Lessons from Randomized Trials in Other Fibrotic Diseases

New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?

Fibrosis in IBD: from pathogenesis to therapeutic targets

Intestinal Fibrosis: the Achilles Heel of Inflammatory Bowel Diseases?

Intestinal strictures in Crohn's disease: a 2021 update

Mechanism of fibrosis and stricture formation in Crohn's disease

Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease

Intestinal stricture in Crohn's disease: A 2020 update

Molecular basis of intestinal fibrosis in inflammatory bowel disease

Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review

Caveolin-1 Alleviates Crohn's Disease-induced Intestinal Fibrosis by Inhibiting Fibroblasts Autophagy Through Modulating Sequestosome 1.

Preventing fibrosis in IBD: update on immune pathways and clinical strategies

Cellular and Molecular Mechanisms of Intestinal Fibrosis

Recent advances in intestinal fibrosis

Intestinal strictures in Crohn's disease: An update from 2023

DOP33 Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s disease

Mechanisms and therapeutic research progress in intestinal fibrosis

Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn's Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets

Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn’s Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets

Noncoding RNAs As Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: the Path from Bench to Bedside.

Evaluation of the Antifibrotic Effects of Drugs Commonly Used in Inflammatory Intestinal Diseases on In Vitro Intestinal Cellular Models